# ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab

> **NCT04272463** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 217 (actual)

## Conditions studied

- Severe Asthma

## Interventions

- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT04272463
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-13
- **Primary completion:** 2020-07-15
- **Final completion:** 2020-07-15
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04272463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04272463, "ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04272463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*